Enteropathy-Associated T-Cell Lymphoma
Showing 1 - 25 of >10,000
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by
Not yet recruiting
- Adult T-cell Leukemia/Lymphoma
- +4 more
- CC-486 (5-azacitidine)
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial
Completed
- Anaplastic Large Cell Lymphoma, ALK-Negative
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, California
- +7 more
Nov 4, 2022
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +14 more
- Cholecalciferol
- Laboratory Biomarker Analysis
-
Scottsdale, Arizona
- +4 more
Jan 16, 2023
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive
Recruiting
- LGLL - Large Granular Lymphocytic Leukemia
- +13 more
-
Duarte, California
- +9 more
Aug 9, 2022
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States
Recruiting
- Angioimmunoblastic T-cell Lymphoma
- +6 more
- Cyclophosphamide
- +6 more
-
Los Angeles, California
- +20 more
Aug 2, 2022
T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific Trial
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +6 more
- T cell injection targeting CD7 chimeric antigen receptor
-
Zhengzhou, Henan, ChinaFirst Affiliated Hospital of Zhengzhou University
Jan 4, 2021
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell
Unknown status
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- +5 more
- CEOP/IVE/GDP chemotherapy regimen
- CEOP chemotherapy regimen for 6 cycles
-
Fuzhou, Fujian, China
- +3 more
Mar 7, 2020
T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- Pembrolizumab
- (no location specified)
Jul 22, 2022
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined
Recruiting
- Peripheral T Cell Lymphoma
- +2 more
- Chidamide combined with Duvillisib
-
Xiamen, Fujian, ChinaThe First Affiliated Hosptial of Xiamen University
Nov 28, 2023
ASCT Versus Chemotherapy as First-Line Consolidation Therapy
Completed
- T-cell Lymphoma Adults
- consolidation with ASCT
- (no location specified)
Nov 25, 2023
T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)
Not yet recruiting
- T Cell Lymphoma
- Mogamulizumab
- DA-EPOCH Protocol
-
New Haven, ConnecticutYale Smilow Cancer Hospital
Aug 14, 2023
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- +3 more
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023
Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas
Not yet recruiting
- Peripheral T Cell Lymphoma
- circulating tumoral DNA detection
-
Rouen, FranceCentre Henri Becquerel
Oct 13, 2023
Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Cutaneous T-cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 8, 2023
Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)
Recruiting
- Newly Diagnosed Peripheral T-cell Lymphoma
- Duvelisib, Chidamide
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023
NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- 4 cycles of ESA regimen with sandwiched radiotherapy
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Sep 29, 2023